HRT Financial LP, a ten percent owner of NewGenIvf Group Ltd, reported open-market purchases of the company’s Common Stock. On June 2, it bought 23,018 shares at an average price of $0.944 per share. On June 3, it bought an additional 11,738 shares at an average price of $0.875 per share. After these transactions, HRT Financial LP directly holds 83,079 shares of NewGenIvf common stock.
HRT Financial LP has filed an initial ownership report for NewGenIvf Group Ltd, indicating it is a ten percent owner of the company. The filing shows direct beneficial ownership of 71,341 shares of Common Stock as of the reported date, with no buys or sells disclosed in this report.
NewGenIVF Group Limited is exercising its top-up option to buy an additional 4% equity in K25.ai for US$4,000,000, split between US$2,000,000 in cash or digital assets and 1,500,000 newly issued Class A ordinary shares. A US$300,000 deposit is due at signing, with the remaining US$1,700,000 payable by August 30, 2026, subject to customary closing conditions. This raises NewGen’s stake in K25.ai to 6%, which the company values at about US$6 million, more than its own market capitalization as of June 3, 2026. NewGen is also launching a Digital Asset Treasury strategy focused on reserve diversification and long-term exposure to themes such as AI, digital assets and information markets, and plans to invite K25.ai founder Andy Cheung and two co-founders to its board. The new shares will be issued as restricted securities under Section 4(a)(2) and/or Regulation S exemptions.
HRT Financial LP, a ten percent owner of NewGenIvf Group Ltd, reported an open-market sale of 85,317 shares of Common Stock at $0.80 per share on May 27, 2026. After this transaction, HRT Financial LP directly holds 54,561 shares of NewGenIvf Common Stock.
NewGenIVF Group Limited signed a Share Purchase Agreement and an Exclusive Agency Agreement with K25.ai, an APAC-focused AI-powered live-streaming and prediction platform. NewGen will initially acquire a 2% equity interest in K25.ai for US$2,000,000, split between US$1,000,000 in cash or digital assets and 666,667 newly issued Class A ordinary shares, implying a US$100,000,000 valuation.
NewGen also receives an option to buy up to an additional 8% of K25.ai at US$1,000,000 per 1%, half in cash and half in new shares, which could lift its stake to 10%. Separately, NewGen is appointed exclusive agent to promote and facilitate K25.ai’s platform in selected APAC markets, earning tiered commissions on annual gross profit from its introduced customers, capped at US$5,000,000 per year. The agency deal runs for an initial three-year term with automatic one-year renewals, while territorial exclusivity depends on hitting a US$500,000 annual gross profit threshold per territory.
HRT Financial LP, a ten percent owner of NewGenIvf Group Ltd, reported open-market purchases of the company’s Common Stock. On May 22, 2026 and May 26, 2026, it bought a combined 165,534 shares at prices of $0.99 and $0.92 per share. Following these transactions, HRT Financial LP directly holds 139,878 shares of NewGenIvf Group Ltd common stock.
NewGenIvf Group Ltd disclosed that HRT FINANCIAL LP, identified as a ten percent owner, has reported its beneficial ownership on a Form 3. The filing shows HRT FINANCIAL LP holding 111,885 shares of NewGenIvf Group Ltd common stock directly, with no specific buy or sell transaction reported.
NewGenIVF Group Limited has entered into a strategic investment agreement with K25.ai, an APAC-focused, AI-powered live-streaming watch-to-predict platform. NewGenIVF plans an initial US$2 million investment at a US$100 million pre-money valuation, with an option to increase its total investment to up to US$10 million, all subject to definitive agreements and closing conditions.
The companies also plan an exclusive agency partnership under which NewGenIVF would promote and help develop K25.ai in permitted APAC markets, earning commissions based on gross profit from customers it introduces or services. K25.ai will nominate three independent non-executive director candidates for NewGenIVF’s board, which is expected to expand from five to eight directors following any appointments.
NewGenIvf Group Ltd Chairman & CEO Siu Wing Fung Alfred received a grant of stock options to acquire 56,851 Class B Ordinary Shares at an exercise price of US$0.0001 per share under the company’s 2024 Share Incentive Plan.
The options vest monthly from 4 June 2026 through 4 May 2029, starting with 5,685 options and then 1,462 options on most monthly vesting dates, with 1,458 options vesting in the final tranche. The options expire on 4 May 2033, and following this grant he holds 56,881 stock options directly.